|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
33
|
|
pubmed:dateCreated |
2005-11-18
|
|
pubmed:abstractText |
Various chemotherapeutic regimens have been applied for treatment of mucosa-associated lymphoid tissue (MALT) lymphoma, but no standard regimen has been identified to date. In view of the activity of oxaliplatin (L-OHP) in various types of lymphoma, we performed a phase II study to evaluate the activity of L-OHP for treatment of MALT lymphoma. The primary objective of this study was to determine the objective response rate according to WHO standard criteria.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BartschRupertR,
pubmed-author:DrachJohannesJ,
pubmed-author:GaigerAlexanderA,
pubmed-author:HejnaMichaelM,
pubmed-author:JaegerUlrichU,
pubmed-author:PragerGeraldG,
pubmed-author:RadererMarkusM,
pubmed-author:StreubelBertholdB,
pubmed-author:TuretschekKarlK,
pubmed-author:WöhrerStefanS,
pubmed-author:ZielinskiChristoph CCC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
8442-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16293875-Adult,
pubmed-meshheading:16293875-Aged,
pubmed-meshheading:16293875-Antineoplastic Agents,
pubmed-meshheading:16293875-Austria,
pubmed-meshheading:16293875-Female,
pubmed-meshheading:16293875-Humans,
pubmed-meshheading:16293875-Lymphoma, B-Cell, Marginal Zone,
pubmed-meshheading:16293875-Male,
pubmed-meshheading:16293875-Middle Aged,
pubmed-meshheading:16293875-Organoplatinum Compounds,
pubmed-meshheading:16293875-Prospective Studies,
pubmed-meshheading:16293875-Survival Rate,
pubmed-meshheading:16293875-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma.
|
|
pubmed:affiliation |
Department of Medicine I, University of Vienna, Vienna, Austria. markus.raderer@meduniwien.ac.at
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
